Modalis Therapeutics Corporation Logo

Modalis Therapeutics Corporation

Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.

4883 | T

Overview

Corporate Details

ISIN(s):
JP3922600006
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目11番5号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Modalis Therapeutics Corporation is a biotechnology company that pioneers the development of therapeutics for genetic diseases through epigenome editing. The company's proprietary core platform, CRISPR-GNDM®, is an advanced technology designed to regulate gene expression by selectively activating or suppressing specific genes without altering the underlying DNA sequence. This system utilizes a compact editor that can be delivered to target cells via AAV vectors. Modalis operates a hybrid business model, advancing therapeutic candidates through both in-house development pipelines for subsequent licensing and collaborative partnerships. Its development pipeline is focused on addressing unmet medical needs in muscular disorders, cardiomyopathy, and central nervous system (CNS) disorders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 08:48
Registration Form
訂正有価証券届出書(組込方式)
Japanese 237.5 KB
2025-08-14 08:31
Regulatory News Service
確認書
Japanese 8.9 KB
2025-08-14 08:30
Interim Report
半期報告書-第10期(2025/01/01-2025/12/31)
Japanese 266.6 KB
2025-08-07 08:32
Registration Form
有価証券届出書(組込方式)
Japanese 334.6 KB
2025-03-28 07:52
Post-Annual General Meeting Information
臨時報告書
Japanese 28.4 KB
2025-03-27 08:32
Governance Information
内部統制報告書-第9期(2024/01/01-2024/12/31)
Japanese 24.1 KB
2025-03-27 08:30
Registration Form
確認書
Japanese 8.7 KB
2025-03-27 08:29
Annual Report
有価証券報告書-第9期(2024/01/01-2024/12/31)
Japanese 2.1 MB
2025-02-21 07:31
Audit Report / Information
臨時報告書
Japanese 21.5 KB
2024-08-13 08:14
Registration Form
訂正有価証券届出書(組込方式)
Japanese 293.9 KB
2024-08-13 07:58
Interim Report
半期報告書-第9期(2024/01/01-2024/12/31)
Japanese 249.6 KB
2024-08-13 07:58
Registration Form
確認書
Japanese 8.9 KB
2024-08-07 08:01
Registration Form
有価証券届出書(組込方式)
Japanese 495.2 KB
2024-05-14 06:00
Quarterly Report
四半期報告書-第9期第1四半期(2024/01/01-2024/03/31)
Japanese 166.1 KB
2024-05-14 06:00
Report Publication Announcement
確認書
Japanese 8.9 KB

Automate Your Workflow. Get a real-time feed of all Modalis Therapeutics Corporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Modalis Therapeutics Corporation

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Modalis Therapeutics Corporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.